Health Canada aprueba el píldora oral GLP-1 Foundayo de Eli Lilly, tras autorizaciones en Australia

Health Canada aprueba el píldora oral GLP-1 Foundayo de Eli Lilly, tras autorizaciones en Australia

Health Canada aprobó el fármaco oral GLP-1 Foundayo de Eli Lilly para el manejo de la obesidad y afecciones relacionadas con el peso. La autorización se produce después de que la Administración de Bienes Terapéuticos de Australia (TGA) ya hubiera aprobado el mismo medicamento para adultos con diabetes tipo 2 y obesidad, ofreciendo una nueva opción de tableta diaria. Las decisiones de la TGA fueron reportadas por varios medios de salud australianos, que señalaron que Foundayo se suma a la tableta Wegovy de Novo Nordisk como terapia GLP-1 disponible solo con receta, y se espera que llegue a los pacientes a lo largo del año.

Actores

Therapeutic Goods Administration Foundayo Lilly Samantha Hocking National Association of Clinical Obesity Services Lilly Australia Dr Manny Simons

Ubicaciones

Australia

Verificación de hechos

Cómo funcionan estas métricas
Veredicto general: Parcialmente confirmado Confianza: 71% Afirmaciones: 4
Resumen

All four claims regarding Eli Lilly’s oral GLP-1 drug Foundayo were partially confirmed. The Therapeutic Goods Administration approved Foundayo for adults with type 2 diabetes and obesity in Australia. The approval introduces a second daily GLP-1 weight-loss pill to the Australian market alongside Novo Nordisk’s Wegovy tablet. Foundayo, or orforglipron, will be available for prescription in Australia within days. The drug provides a new daily tablet option for weight management and diabetes.

Inicia sesión o suscríbete para ver el análisis completo con afirmaciones, fuentes y validación cronológica.

Esta sección contiene una verificación automatizada de afirmaciones con fuentes externas y puede incluir imprecisiones.

Artículos

18 de noviembre de 2026
2 en total
Health Canada approves new Eli Lilly GLP-1 pill for weight loss
Health Canada approves new Eli Lilly GLP-1 pill for weight loss

Global News • 18 de nov 21:12

Health Canada approved Eli Lilly’s daily oral GLP-1 medication Foundayo for obesity and weight-related health issues, with availability expected in pharmacies in January.

Credibilidad 88% Manip. 8% Centro
Foundayo approval a welcome addition to GLP-1 treatment options
Foundayo approval a welcome addition to GLP-1 treatment options

Diabetes Australia • 18 de nov 00:43

The Therapeutic Goods Administration has approved Foundayo, an oral GLP-1 receptor agonist, offering a daily tablet option for eligible adults with type 2 diabetes and obesity.

Credibilidad 92% Manip. 8% Centro
17 de noviembre de 2026
2 en total
1 to hit Australian shelves within days
1 to hit Australian shelves within days

Royal Australian College of General Practitioners (RACGP) • 17 de nov 05:34

Eli Lilly's oral GLP-1 medication orforglipron, sold as Foundayo, has been approved by the Therapeutic Goods Administration and will be available for prescription within days, offering a new option for weight management and type-2 diabetes treatment.

Credibilidad 88% Manip. 8% Centro
TGA approves daily weight-loss pills in Australia: Wegovy and oral GLP-1s explained
TGA approves daily weight-loss pills in Australia: Wegovy and oral GLP-1s explained

Nine.com.au • 17 de nov 02:45

The Therapeutic Goods Administration has cleared Eli Lilly’s Foundayo for weight management and type 2 diabetes, adding to Novo Nordisk’s Wegovy tablet, with both drugs requiring prescriptions and expected to reach patients later this year.

Credibilidad 88% Manip. 8% Centro
16 de noviembre de 2026
1 en total
TGA approves first-of-its-kind GLP-1 weight loss pill Foundayo for Australian use
TGA approves first-of-its-kind GLP-1 weight loss pill Foundayo for Australian use

7NEWS • 16 de nov 22:38

The Therapeutic Goods Administration has authorized the oral GLP-1 medication Foundayo, developed by Lilly, for weight loss and type 2 diabetes treatment, with availability expected within days.

Credibilidad 88% Manip. 12% Centro